Not getting enough sleep does more than make you tired. Here’s how short nights can quietly raise your blood pressure, and ...
The first evidence of the existence of renin was presented by Tigerstedt over 100 years ago. However, the importance of renin and the renin–angiotensin system (RAS) in the pathogenesis of ...
Finerenone shows significant benefits in patients with kidney disease and type 1 diabetes, which could lead to the first ...
Not taking enough vitamin D can cause more harm than you’ve heard. Take the risk to heart health, for example. But no worries ...
AstraZeneca and Sun Pharma will jointly market SZC, a key hyperkalaemia drug for CKD and heart failure patients, under ...
CKD prevalence has more than doubled since 1990, with 788 million adults affected in 2023, highlighting a significant global health challenge. The disease is a major contributor to cardiovascular ...
Study Finds on MSN
Pig Kidney Functions Normally In Brain-Dead Human For Record 61 Days
In A Nutshell • A pig kidney with just one genetic modification functioned in a human for 61 days before being removed as ...
Rising chronic kidney disease prevalence and morbidity rates in 2023 make CKD the ninth leading cause of death globally, ...
A real-world analysis published in JACC Advances concludes that heart failure patients prescribed ivabradine face a significantly higher risk of developing atrial fibrillation (AF) within 180 ...
Medpage Today on MSN
Drug Combo Lowers Albuminuria in High-Risk Chronic Kidney Disease
Balcinrenone is similar to finerenone (Kerendia), which is also a nonsteroidal MRA and was approved for the slowing of ...
AstraZeneca will market the therapy as Lokelma, while Sun Pharma will promote and distribute it as Gimliand. AstraZeneca will ...
Adverse changes in the heart’s structure and function are common in people with chronic kidney disease (CKD), warranting mitigating therapies.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results